Spiegel Advances in Clinical Chemistry

1. Auflage 2003
ISBN: 978-0-08-049026-7
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 37, 364 Seiten, Web PDF

Reihe: Advances in Clinical Chemistry

This volume, edited for the last time by H.E. Spiegel, continues the objective of expanding the intellectual horizon of clinical chemistry. The fields of analytical, anatomical, sub-cellular and molecular sciences are all represented in this volume.* Detailed reviews by practicing scientists* Covers a broad range of clinical chemistry on a theoretical and practical basis* Includes easy to read chapters combining science and perspectives in a changing scientific landscape

Autoren/Hrsg.

Spiegel, Herbert E.

Inhaltsverzeichnis

1;Cover;1
2;Copyright Page;5
3;Contents;6
4;Contributors;10
5;Publisher's Note;12
6;Preface;14
7;Chapter 1. Clinical Applications of Cytokine Assays;16
7.1;1. Cytokines: An Overview;16
7.2;2. Cytokines and Diseases;29
7.3;3. Cytokine Assays;35
7.4;4. Clinical Application of Cytokine Assays;43
7.5;5. Conclusions;47
7.6;References;47
8;Chapter 2. Current Concepts on Diagnosis and Treatment of Acute Pancreatitis;62
8.1;1. Introduction;62
8.2;2. Pathophysiology of Acute Pancreatitis;64
8.3;3. Diagnosis of Acute Pancreatitis;66
8.4;4. Therapy;82
8.5;5. Conclusions;85
8.6;References;85
9;Chapter 3. Mitochondrial DNA Mutations and Oxidative Stress in Mitochondrial Diseases;98
9.1;1. Introduction;99
9.2;2. A Brief Review of Studies on Mitochondrial Diseases;100
9.3;3. The Genetic Map and Structural Characteristics of Human Mitochondrial DNA.;101
9.4;4. Transmission by Maternal Inheritance and Random Segregation of mtDNA during Mitosis and Development;102
9.5;5. Susceptibility of mtDNA to Oxidative Damage and Mutation;105
9.6;6. Classification of Disease-Associated mtDNA Mutations;105
9.7;7. Molecular Consequences of mtDNA Mutations;112
9.8;8. Biochemical Basis for How mtDNA Mutations Cause Mitochondrial Dysfunction;115
9.9;9. Oxidative Stress and Oxidative Damage Elicited by mtDNA Mutations;117
9.10;10. Mitochondrial Diseases Caused by Mutations in Nuclear DNA;119
9.11;11. Cybrids for Studies of Mitochondrial Diseases: Applications and Limitations;122
9.12;12. Effect of mtDNA Mutations on the Apoptosis of Human Cells;126
9.13;13. Therapy for Mitochondrial Diseases.;128
9.14;14. Concluding Remarks;130
9.15;References;131
10;Chapter 4. Autoantibodies to dsDNA, Ro/SSA, and La/SSB in Systemic Lupus Erythematosus;144
10.1;1. Introduction;144
10.2;2. Basic Studies of Autoantibodies to dsDNA, Ro/SSA, and La/SSB;148
10.3;3. Clinical Aspects of Anti-dsDNA, Anti-Ro/SSA, and Anti-La/SSB Autoantibodies;160
10.4;4. Discussion and Conclusion;168
10.5;References;169
11;Chapter 5. Pathobiochemistry of Nephrotic Syndrome;188
11.1;1. Introduction;189
11.2;2. Structure and Function of the Glomerular Capillary Wall;189
11.3;3. Pathogenesis of Proteinuria in Acquired Forms of Nephrotic Syndrome;200
11.4;4. Biochemical Signs and Clinical Symptoms of Nephrotic Syndrome;211
11.5;5. Diagnosis of Nephrotic Syndrome;220
11.6;6. Treatment of Nephrotic Syndrome;221
11.7;7. Summary;222
11.8;References;223
12;Chapter 6. Total Antioxidant Capacity;234
12.1;1. Introduction;235
12.2;2. Methodology;236
12.3;3. What Determines Total Antioxidant Capacity?;251
12.4;4. Total Antioxidant Capacity of Body Fluids;256
12.5;5. Total Antioxidant Capacity of Tissue Homogenates;261
12.6;6. Total Antioxidant Capacity of Food and Beverages;263
12.7;7. Total Antioxidant Capacity of Plants;266
12.8;8. Antioxidant Activity of Individual Compounds;267
12.9;9. Effect of Nutrition on Total Antioxidant Activity of Body Fluids;269
12.10;10. Effect of Physical Exercise on Blood Plasma Total Antioxidant Capacity;274
12.11;11. Alterations in Total Antioxidant Capacity of Body Fluids and Tissue Homogenates in Diseases and Therapy;275
12.12;12. Points of Concern;284
12.13;13. Conclusions;287
12.14;References;287
13;Chapter 7. Lymphoid Malignancies: Immunophenotypic Analysis;308
13.1;1. Introduction: Immunophenotypic Analysis;308
13.2;2. Background: Immunophenotypic Analysis;310
13.3;3. Normal Lymphoid Cell Development and Antigen Expression;318
13.4;4. Neoplastic Lymphoid Cell Antigen Expression;323
13.5;5. Selected Biochemical Consequences of Neoplastic Transformation;340
13.6;6. Conclusion;344
13.7;References;344
14;Index;370